ArticleJournal of neuropathology and experimental neurology2010
Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells.
Article in Journal of neuropathology and experimental neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome.Scientific reports · 2016Trial
- Trial
- PathExpSurv: pathway expansion for explainable survival analysis and disease gene discovery.BMC bioinformatics · 2023Article
- Genetic heterogeneity of liver cancer stem cells.Anatomy & cell biology · 2023Article
- ErbB4 in the brain: Focus on high grade glioma.Frontiers in oncology · 2022Review
- Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma.Viruses · 2021Article
- Article
- An immunohistochemical study of HER2 expression in primary brain tumors.BioMedicine · 2020Article
- Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model.Oncogene · 2019Article
- Multi-stage Association Analysis of Glioblastoma Gene Expressions with Texture and Spatial Patterns.Brainlesion : glioma, multiple sclerosis, stroke and traumatic brain injuries. BrainLes (Workshop) · 2019Article
- Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response.Cancers · 2018Article
- Review
- The Unwanted Cell Migration in the Brain: Glioma Metastasis.Neurochemical research · 2017Review
- Nrdp1S, short variant of Nrdp1, inhibits human glioma progression by increasing Nrdp1-mediated ErbB3 ubiquitination and degradation.Journal of cellular and molecular medicine · 2016Article
- Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma.Journal of neuro-oncology · 2013Article
- Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.Cancer gene therapy · 2012Article
- Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.Molecular pharmacology · 2012Article
- Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- c-erbB-2 protein expression in astrocytic tumors of the brain.Medical science monitor : international medical journal of experimental and clinical research · 2011Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastomas are the most common primary central nervous system tumors in adults, and they remain resistant to current treatments. erbB1 signaling is frequently altered in glioblastomas, suggesting thaterbB receptor family members may represent targets for molecular therapy. We performed a comprehensive analysis of erbB receptor and ligand expression profiles in a panel of 9 glioblastomas andcompared them to nonneoplastic cerebral tissue containing neocortex and adjacent white matter. Quantitative reverse transcription-polymerase chain reaction and Western blot analysis showed that erbB1signaling and erbB2 receptors exhibited highly variable deregulation profiles in the tumors, with patterns ranging from underexpression to overexpression; in contrast, erbB3 and erbB4 were downregulated. We next performed immunohistochemistry to determinethe distribution patterns of erbB receptors among the main neuralcell types in the tumors with special reference to the putative tumor stem cell population. Results revealed intertumoral and intratumoral heterogeneity in all 4 erbB expression profiles, but each receptor exhibited a distinct distribution pattern among glial fibrillary acidic protein-, Olig2-, NeuN-, and CD133-positive populations. Although erbB1 immunoreactivity was detected in only small subsets of CD133-positive putative tumor stem cells, erbB3 immunoreactivity was prominent in this population, suggesting that erbB3 may represent a new potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.